Share on LinkedInShare on LinkedIn

ARTICLE · 05 NOVEMBER 2026

Section 232 Pharmaceutical Tariffs Are Now In Effect: It’s Not Too Late To Consider Duty-Mitigation Strategies

WilmerHale
WilmerHale
Contributor
WilmerHale

WilmerHale

WilmerHale's London office was established more than 40 years ago. With lawyers qualified in the...

View firm profile
Explore more from WilmerHale

On September 29, 2026, the final phase of Section 232 pharmaceutical tariffs took effect, imposing an additional 100 percent ad valorem duty on many imported patented pharmaceuticals and ingredients. While these duties may substantially increase import costs, several customs and trade mechanisms may be available to reduce, eliminate, or defer the tariffs.

GlobalInternational Law

On September 29, 2026, the final phase of the Section 232 pharmaceutical tariffs established by Presidential Proclamation 11020 (the Proclamation), became effective, subjecting many imported patented pharmaceuticals and associated ingredients to an additional 100 percent ad valorem duty. Companies that were not identified in Annex III to the Proclamation are now generally subject to a 100 percent duty rate for their covered patented pharmaceutical imports unless the products qualify for the numerous exclusions, reduced-rate provisions and product-specific exceptions that have been refined through subsequent Federal Register notices, US Department of Commerce’s Bureau of Industry and Security (BIS) guidance, and US Customs and Border Protection (CBP) Cargo Systems Messaging Service messages.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from